Updated results from GOBLET study of pelareorep + Tecentriq in patients with ≥2L metastatic SCAC announced November 4, 2025
WELIREG + LENVIMA Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC November 4, 2025
Updated Rezatapopt Monotherapy Interim Data Announced From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation October 29, 2025
Updated Elironrasib Safety & Efficacy Data in Patients with KRAS G12C NSCLC Following Treatment with a KRAS(OFF) G12C Inhibitor Presented October 29, 2025
Preliminary Data from Ongoing Ph 1/2a Dose Escalation Trial of VS-7375 in Patients with KRAS G12D Mutant Solid Tumors Announced October 29, 2025
NANETS 2025: Ph 3 COMPETE Data Shows Higher ORRs with ITM-11 vs. Everolimus Across Subgroups of Patients with GEP-NETs presented October 29, 2025
Robust T cell Responses Reported Across Diverse HLA backgrounds in Ph 2 AMPLIFY-7P Trial of ELI-002 October 29, 2025
Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced October 29, 2025
PROs from VERITAC-2 Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy October 29, 2025
Positive Data from Ongoing Ph 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers Reported October 29, 2025
Positive Topline Results from Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Reported and Updates Provided on CRC and Ewing Sarcoma Expansion Cohorts October 29, 2025
Interim Petosemtamab Data in Metastatic CRC Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety October 29, 2025
Positive Ph 2 Results for HBM4003 and Tislelizumab Combination in MSS mCRC announced October 29, 2025
Results for HLD-0915 Demonstrate Encouraging Safety and Anti-Tumor Activity in Metastatic CRPC October 29, 2025
Positive Outcome From FORTE Basket Study of Plixorafenib Monotherapy in Recurrent or Progressive BRAF V600 Primary CNS Tumors Announced October 21, 2025
TECVAYLI® + DARZALEX FASPRO® combination regimen significantly improves PFS and OS vs SOC October 21, 2025
TUKYSA Combination Significantly Improves PFS as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial October 16, 2025
Ph 3 Trial of HANSIZHUANG + Chemo Meets Primary Endpoint in Neoadjuvant/ Adjuvant Gastric Cancer, Greenlighting Early NDA Submission October 16, 2025
Enrollment in cohorts 1 & 2 of GTB-3650 Ph 1 Trial in Patients with R/R CD33 Expressing Heme Malignancies Completed October 15, 2025
Initial clinical data on the combination of AB8939 + venetoclax in the first three patients with R/R AML announced October 15, 2025
FAILED TRIAL: Zolbetuximab Ph 2 GLEAM Trial Did Not Meet Primary Endpoint of OS in Patients with Metastatic Pancreatic Cancer October 15, 2025
OPTIMIZE-1 biomarker analysis published in Cell Reports Medicine supporting mitazalimab and mFOLFIRINOX in metastatic pancreatic cancer October 15, 2025
